$CYTK
CYTOKINETICS INC

2014 Q1 Form 10-K Financial Statement

#000119312514089045 Filed on March 07, 2014

View on sec.gov

Income Statement

Concept 2014 Q1 2013 2012 Q4
Revenue $7.979M $30.65M $2.184M
YoY Change 871.86% 305.45% 187.37%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.260M $15.10M $3.820M
YoY Change 17.36% 21.77% 33.57%
% of Gross Profit
Research & Development $12.49M $49.45M $9.860M
YoY Change 27.01% 38.74% 14.65%
% of Gross Profit
Depreciation & Amortization $105.0K $433.0K $130.0K
YoY Change -15.32% -26.73% -43.48%
% of Gross Profit
Operating Expenses $12.49M $64.54M $13.67M
YoY Change 27.01% 81.08% 19.28%
Operating Profit -$8.770M -$33.89M
YoY Change -30.66% -16.22%
Interest Expense $30.00K $0.00 $30.00K
YoY Change 0.0% -100.0% 50.0%
% of Operating Profit
Other Income/Expense, Net $26.00K $177.0K $0.00
YoY Change -7.14% 103.45%
Pretax Income -$8.744M -$33.72M -$11.46M
YoY Change -30.71% -16.48% -3.54%
Income Tax $0.00 $0.00 $0.00
% Of Pretax Income
Net Earnings -$8.744M -$33.72M -$11.46M
YoY Change -30.71% -16.48% -3.58%
Net Earnings / Revenue -109.59% -110.01% -524.5%
Basic Earnings Per Share
Diluted Earnings Per Share -$264.9K -$1.234M -$480.5K
COMMON SHARES
Basic Shares Outstanding 36.08M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2014 Q1 2013 2012 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments $82.35M $77.70M $74.00M
YoY Change 33.68% 5.0% 51.02%
Cash & Equivalents $13.26M $20.20M $14.91M
Short-Term Investments $69.09M $57.60M $59.09M
Other Short-Term Assets $1.592M $1.400M $2.423M
YoY Change -6.35% -36.36% 15.38%
Inventory
Prepaid Expenses
Receivables $2.100M $0.00 $0.00
Other Receivables $0.00 $200.0K $200.0K
Total Short-Term Assets $86.05M $79.30M $76.43M
YoY Change 35.09% 3.8% 49.56%
LONG-TERM ASSETS
Property, Plant & Equipment $1.508M $1.200M $997.0K
YoY Change 67.56% 20.0% -23.31%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $19.50M $2.500M $0.00
YoY Change
Other Assets $200.0K $100.0K $127.0K
YoY Change 100.0% 0.0% -57.67%
Total Long-Term Assets $21.22M $3.900M $1.124M
YoY Change 2022.3% 225.0% -33.88%
TOTAL ASSETS
Total Short-Term Assets $86.05M $79.30M $76.43M
Total Long-Term Assets $21.22M $3.900M $1.124M
Total Assets $107.3M $83.20M $77.55M
YoY Change 65.81% 7.22% 46.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.689M $3.700M $2.002M
YoY Change 53.55% 85.0% 66.83%
Accrued Expenses $7.678M $8.300M $4.877M
YoY Change 63.36% 69.39% 52.41%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $19.79M $26.70M $7.105M
YoY Change 241.24% 276.06% 54.46%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $1.300M $2.000M $400.0K
YoY Change 225.0% 400.0%
Total Long-Term Liabilities $1.300M $2.000M $400.0K
YoY Change 225.0% 400.0%
TOTAL LIABILITIES
Total Short-Term Liabilities $19.79M $26.70M $7.105M
Total Long-Term Liabilities $1.300M $2.000M $400.0K
Total Liabilities $21.10M $28.70M $7.466M
YoY Change 234.9% 282.67% 62.3%
SHAREHOLDERS EQUITY
Retained Earnings -$491.3M -$448.9M
YoY Change
Common Stock $36.00K $24.00K
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $86.18M $54.40M $70.09M
YoY Change
Total Liabilities & Shareholders Equity $107.3M $83.20M $77.55M
YoY Change 65.81% 7.22% 46.88%

Cashflow Statement

Concept 2014 Q1 2013 2012 Q4
OPERATING ACTIVITIES
Net Income -$8.744M -$33.72M -$11.46M
YoY Change -30.71% -16.48% -3.58%
Depreciation, Depletion And Amortization $105.0K $433.0K $130.0K
YoY Change -15.32% -26.73% -43.48%
Cash From Operating Activities -$17.82M -$7.718M -$7.130M
YoY Change 45.82% -76.92% -34.89%
INVESTING ACTIVITIES
Capital Expenditures $333.0K $542.0K -$60.00K
YoY Change 88.14% 333.6% 200.0%
Acquisitions
YoY Change
Other Investing Activities -$28.53M -$980.0K $6.680M
YoY Change -367.89% -96.58% -24.18%
Cash From Investing Activities -$28.86M -$1.519M $6.610M
YoY Change -375.64% -94.73% -24.8%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $39.87M $7.450M
YoY Change -82.94%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 39.78M 14.49M 30.00K
YoY Change 795500.0% -75.16% -98.74%
NET CHANGE
Cash From Operating Activities -17.82M -7.718M -7.130M
Cash From Investing Activities -28.86M -1.519M 6.610M
Cash From Financing Activities 39.78M 14.49M 30.00K
Net Change In Cash -6.902M 5.251M -490.0K
YoY Change 295.08% -233.75% -313.04%
FREE CASH FLOW
Cash From Operating Activities -$17.82M -$7.718M -$7.130M
Capital Expenditures $333.0K $542.0K -$60.00K
Free Cash Flow -$18.16M -$8.260M -$7.070M
YoY Change 46.42% -75.39% -35.32%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2010Q4 us-gaap Grants Receivable
GrantsReceivable
700000
CY2011Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
170000000 shares
CY2011Q2 cytk Gross Proceeds From Issuance Of Stock
GrossProceedsFromIssuanceOfStock
20100000
CY2014Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
36078367 shares
CY2012Q2 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
7894704 shares
CY2012Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
9320176 shares
CY2012Q2 us-gaap Share Price
SharePrice
4.56
CY2013Q2 dei Entity Public Float
EntityPublicFloat
331200000
CY2011Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
245000000 shares
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
25.89
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1349223 shares
CY2010Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
854862 shares
CY2010Q4 us-gaap Stockholders Equity
StockholdersEquity
70516000
CY2010Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
17514000
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
21.93
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1598408 shares
CY2011Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
585476 shares
CY2011Q4 us-gaap Share Price
SharePrice
9.00
CY2011Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2011Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
169107000
CY2011Q4 us-gaap Stockholders Equity
StockholdersEquity
48178000
CY2011Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
152000
CY2011Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4300000
CY2011Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
16778000
CY2011Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
141226000
CY2011Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
169107000
CY2011Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
18833000
CY2011Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2011Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
3524000
CY2011Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
997000
CY2011Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
6582000
CY2012Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
23742911 shares
CY2012Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
23742911 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
18.96
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
1790527 shares
CY2012Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
878726 shares
CY2012Q4 us-gaap Share Price
SharePrice
4.56
CY2012Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2012Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
81500000 shares
CY2012Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2012Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2012Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4877000
CY2012Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2012Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
23288000
CY2012Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
257000
CY2012Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
518923000
CY2012Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
2002000
CY2012Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
312000
CY2012Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
190193000
CY2012Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
87000
CY2012Q4 us-gaap Liabilities Current
LiabilitiesCurrent
7105000
CY2012Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
18000
CY2012Q4 us-gaap Stockholders Equity
StockholdersEquity
70085000
CY2012Q4 us-gaap Due To Related Parties Current
DueToRelatedPartiesCurrent
150000
CY2012Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
696000
CY2012Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-448880000
CY2012Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1355000
CY2012Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
361000
CY2012Q4 us-gaap Common Stock Value
CommonStockValue
24000
CY2012Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
76000
CY2012Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
77551000
CY2012Q4 us-gaap Liabilities
Liabilities
7466000
CY2012Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
4200000
CY2012Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2012Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
25943000
CY2012Q4 us-gaap Assets Current
AssetsCurrent
76427000
CY2012Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127000
CY2012Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
153193000
CY2012Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
59093000
CY2012Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
190193000
CY2012Q4 us-gaap Assets
Assets
77551000
CY2012Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14907000
CY2012Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2012Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
24285000
CY2012Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
4000
CY2012Q4 us-gaap Interest Receivable
InterestReceivable
187000
CY2012Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
5101000
CY2012Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
74000000
CY2012Q4 us-gaap Other Assets Current
OtherAssetsCurrent
2423000
CY2012Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
997000
CY2012Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
1024000
CY2012Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
4932000
CY2012Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
2170000
CY2013Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
30681624 shares
CY2013Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
537001000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due
OperatingLeasesFutureMinimumPaymentsDue
16033000
CY2013Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3709000
CY2013Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
697000
CY2013Q4 us-gaap Stockholders Equity
StockholdersEquity
54442000
CY2013Q4 us-gaap Accrued Vacation Current
AccruedVacationCurrent
778000
CY2013Q4 us-gaap Restructuring Reserve
RestructuringReserve
0
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Four Years
OperatingLeasesFutureMinimumPaymentsDueInFourYears
3713000
CY2013Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
203863000
CY2013Q4 us-gaap Other Employee Related Liabilities Current
OtherEmployeeRelatedLiabilitiesCurrent
93000
CY2013Q4 us-gaap Liabilities Current
LiabilitiesCurrent
26704000
CY2013Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
7000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Thereafter
OperatingLeasesFutureMinimumPaymentsDueThereafter
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
1622205 shares
CY2013Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30681624 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
15.15
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
2449365 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
2161829 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
15.22
CY2013Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
2428631 shares
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
19.49
CY2013Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
81500000 shares
CY2013Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2013Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2013Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
8272000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Two Years
OperatingLeasesFutureMinimumPaymentsDueInTwoYears
3470000
CY2013Q4 us-gaap Income Tax Examination Penalties And Interest Accrued
IncomeTaxExaminationPenaltiesAndInterestAccrued
0
CY2013Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
20992000
CY2013Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
115000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Five Years
OperatingLeasesFutureMinimumPaymentsDueInFiveYears
1906000
CY2013Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-482597000
CY2013Q4 us-gaap Deferred Revenue Current
DeferredRevenueCurrent
14701000
CY2013Q4 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
1614000
CY2013Q4 us-gaap Deferred Rent Credit Noncurrent
DeferredRentCreditNoncurrent
542000
CY2013Q4 us-gaap Common Stock Value
CommonStockValue
31000
CY2013Q4 us-gaap Deferred Rent Credit Current
DeferredRentCreditCurrent
22000
CY2013Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
83188000
CY2013Q4 us-gaap Line Of Credit Facility Amount Outstanding
LineOfCreditFacilityAmountOutstanding
0
CY2013Q4 us-gaap Liabilities
Liabilities
28746000
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due In Three Years
OperatingLeasesFutureMinimumPaymentsDueInThreeYears
3587000
CY2013Q4 us-gaap Deferred Revenue Noncurrent
DeferredRevenueNoncurrent
1500000
CY2013Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
5000000
CY2013Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2013Q4 us-gaap Operating Leases Future Minimum Payments Due Current
OperatingLeasesFutureMinimumPaymentsDueCurrent
3357000
CY2013Q4 us-gaap Long Term Investments
LongTermInvestments
2502000
CY2013Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
33043000
CY2013Q4 us-gaap Assets Current
AssetsCurrent
79338000
CY2013Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
127000
CY2013Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
144254000
CY2013Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
57570000
CY2013Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
203863000
CY2013Q4 us-gaap Assets
Assets
83188000
CY2013Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
20158000
CY2013Q4 us-gaap Deferred Tax Assets Net
DeferredTaxAssetsNet
CY2013Q4 us-gaap Property Plant And Equipment Gross
PropertyPlantAndEquipmentGross
22213000
CY2013Q4 us-gaap Accounts Receivable Related Parties Current
AccountsReceivableRelatedPartiesCurrent
5000
CY2013Q4 us-gaap Interest Receivable
InterestReceivable
215000
CY2013Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
288844
CY2013Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
4946000
CY2013Q4 us-gaap Cash Cash Equivalents And Short Term Investments
CashCashEquivalentsAndShortTermInvestments
80200000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
589077
CY2013Q4 us-gaap Other Assets Current
OtherAssetsCurrent
1605000
CY2013Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
580858
CY2013Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1221000
CY2013Q4 cytk Number Of Financial Institutions
NumberOfFinancialInstitutions
3 Financial_Institution
CY2013Q4 cytk Deferred Tax Assets Depreciation And Amortization
DeferredTaxAssetsDepreciationAndAmortization
918000
CY2013Q4 cytk Deferred Tax Assets Capitalized Research And Development
DeferredTaxAssetsCapitalizedResearchAndDevelopment
20702000
CY2013Q4 cytk Accrued Clinical And Preclinical Costs Current
AccruedClinicalAndPreclinicalCostsCurrent
4975000
CY2013Q4 cytk Estimated Increase In Equity
EstimatedIncreaseInEquity
1800000
CY2011Q2 cytk Preferred Stock Conversion Ratio
PreferredStockConversionRatio
1000 pure
CY2011Q2 cytk Warrants Issuance Cost
WarrantsIssuanceCost
100000
CY2012Q2 cytk Number Of Concurrent Public Offerings
NumberOfConcurrentPublicOfferings
2 PublicOffering
CY2013Q2 cytk Number Of Issued Shares Of Common Stock Related To Cashless Exercise Of Warrants
NumberOfIssuedSharesOfCommonStockRelatedToCashlessExerciseOfWarrants
358460 shares
CY2012Q3 cytk Research Development Grant
ResearchDevelopmentGrant
500000
CY2013Q2 us-gaap Stockholders Equity Note Stock Split
StockholdersEquityNoteStockSplit
As a result of the one-for-six reverse stock split effected in June 2013, the conversion ratio for Series B convertible preferred stock changed from 1,000 shares of common stock per share of Series B convertible preferred stock to 166.67 shares of common stock per share of Series B convertible preferred stock.
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1 pure
CY2011Q4 us-gaap Restructuring And Related Activities Initiation Date
RestructuringAndRelatedActivitiesInitiationDate
2011-10-01
CY2011Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated
RestructuringAndRelatedCostNumberOfPositionsEliminated
18 Employees
CY2011Q4 us-gaap Restructuring And Related Cost Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent
0.18 pure
CY2011Q4 cytk Number Of Employees After Restructuring
NumberOfEmployeesAfterRestructuring
83 Employees
CY2013Q2 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
As of the effective time of the reverse stock split, every six shares of the Company's issued and outstanding common stock were converted into one issued and outstanding share of common stock, without any change in par value per share.
CY2013Q2 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
1 pure
CY2010 cytk Period For Potential Treatment
PeriodForPotentialTreatment
P3Y
CY2010 cytk Research Development Grant
ResearchDevelopmentGrant
2800000
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
500000 shares
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
425420 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2011 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2011 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11800000 shares
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.56
CY2011 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2011 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-45595000
CY2011 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.30
CY2011 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
6.56
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
425420 shares
CY2011 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.01 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
173568 shares
CY2011 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
6.00
CY2011 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06 pure
CY2011 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
22.63
CY2011 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.01 pure
CY2011 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4584000 shares
CY2011 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
7.20
CY2011 us-gaap Revenues
Revenues
4000000
CY2011 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
238000
CY2011 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-47853000
CY2011 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
-3000
CY2011 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2011 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-50717000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
CY2011 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
4427000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-47860000
CY2011 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
17000
CY2011 us-gaap Investment Income Interest
InvestmentIncomeInterest
132000
CY2011 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
48025000
CY2011 us-gaap Profit Loss
ProfitLoss
-47860000
CY2011 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
833000
CY2011 us-gaap Revenue From Grants
RevenueFromGrants
1680000
CY2011 us-gaap Operating Income Loss
OperatingIncomeLoss
-47964000
CY2011 us-gaap Interest And Other Income
InterestAndOtherIncome
143000
CY2011 us-gaap Interest Paid
InterestPaid
41000
CY2011 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
104000
CY2011 us-gaap Net Income Loss
NetIncomeLoss
-47860000
CY2011 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
7000
CY2011 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
6127000
CY2011 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
53000
CY2011 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
18500000
CY2011 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-47860000
CY2011 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-32000
CY2011 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3069000
CY2011 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
443000
CY2011 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-592000
CY2011 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
9329000
CY2011 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
13000
CY2011 us-gaap Costs And Expenses
CostsAndExpenses
51964000
CY2011 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
13590000
CY2011 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
21613000
CY2011 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2011 us-gaap Interest And Debt Expense
InterestAndDebtExpense
39000
CY2011 us-gaap Share Based Compensation
ShareBasedCompensation
3069000
CY2011 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
1319000
CY2011 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2011 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
2990000
CY2011 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2266000
CY2011 us-gaap Interest Expense
InterestExpense
35000
CY2011 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
3000
CY2011 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2011 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
194000
CY2011 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
25301000
CY2011 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
37182000
CY2011 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
12000
CY2011 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2011 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
1297000
CY2011 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2011 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
73174000
CY2011 us-gaap Restructuring Charges
RestructuringCharges
1192000
CY2011 us-gaap Depreciation
Depreciation
1300000
CY2011 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3069000
CY2011 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
2857000
CY2011 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2011 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
162000
CY2011 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2011 cytk Adjustments To Additional Paid In Capital Issuance Of Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock
9329000
CY2011 cytk Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs
ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts
2421000
CY2011 cytk Related Party Research And Development Revenue
RelatedPartyResearchAndDevelopmentRevenue
2054000
CY2011 cytk Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
6127000
CY2011 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.00 pure
CY2011 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
1946000
CY2011 cytk Warrant Expense
WarrantExpense
CY2011 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
173569 shares
CY2011 cytk Proceeds From Other Issuances Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOtherIssuancesOfCommonStockAndWarrantsNetOfIssuanceCosts
10696000
CY2011 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
6.66
CY2011 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
shares
CY2011 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.39 pure
CY2011 cytk Issuance Cost Of Warrant
IssuanceCostOfWarrant
38000
CY2011 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00 pure
CY2013 dei Trading Symbol
TradingSymbol
CYTK
CY2013 dei Entity Registrant Name
EntityRegistrantName
CYTOKINETICS INC
CY2013 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2013 dei Amendment Flag
AmendmentFlag
false
CY2013 dei Entity Filer Category
EntityFilerCategory
Accelerated Filer
CY2013 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2013
CY2013 dei Document Type
DocumentType
10-K
CY2013 dei Document Period End Date
DocumentPeriodEndDate
2013-12-31
CY2013 dei Entity Central Index Key
EntityCentralIndexKey
0001061983
CY2013 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2013 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2013 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2013 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
2000000 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
797629 shares
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P6Y8M1D
CY2013 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2013 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
27275000 shares
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
5.95
CY2013 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2013 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7718000
CY2013 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.24
CY2013 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
5.32
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
797629 shares
CY2013 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.14 pure
CY2013 us-gaap Number Of Reportable Segments
NumberOfReportableSegments
1 Segment
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
117394 shares
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
4.02
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2013 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P6Y7M24D
CY2013 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<div> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-LEFT: 24px; MARGIN-TOP: 18px; LETTER-SPACING: normal; TEXT-INDENT: 0px; -webkit-text-stroke-width: 0px"> <b><i><font style="FONT-FAMILY: 'Times New Roman'" size="2"><b><i>Concentration of Credit Risk and Other Risks and Uncertainties</i></b></font></i></b></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 6px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px" align="justify"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Financial instruments that potentially subject the Company to concentrations of risk consist principally of cash and cash equivalents, investments and accounts receivable. The Company&#x2019;s cash, cash equivalents and investments are invested in deposits with three major financial institutions in the U.S.&#xA0;Deposits in these banks may exceed the amount of insurance provided on such deposits. The Company has not experienced any realized losses on its deposits of cash, cash equivalents or investments.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px" align="justify"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The economic turmoil in the United States in recent years, the extraordinary volatility in the stock markets and other current negative macroeconomic indicators could negatively impact the Company&#x2019;s ability to raise the funds necessary to support its business and may materially adversely affect its business, operating results and financial condition.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px" align="justify"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company performs an ongoing credit evaluation of its strategic partners&#x2019; financial conditions and generally does not require collateral to secure accounts receivable from its strategic partners. The Company&#x2019;s exposure to credit risk associated with non-payment will be affected principally by conditions or occurrences within Amgen Inc. (&#x201C;Amgen&#x201D;) and Astellas Pharma Inc. (&#x201C;Astellas&#x201D;), its strategic partners. Approximately 63%, 55% and 51% of total revenues for the years ended December&#xA0;31, 2013, 2012 and 2011, respectively, were derived from Amgen. Accounts receivable due from Amgen were zero at December&#xA0;31, 2013 and 2012. See also Note&#xA0;7, &#x201C;Related Party Transactions,&#x201D; regarding the collaboration agreement with Amgen. Approximately 34% of total revenues for the year ended December&#xA0;31, 2013 was derived from Astellas. Accounts receivable due from Astellas were zero at December&#xA0;31, 2013. See also Note&#xA0;8, &#x201C;Other Research and Development Revenue Arrangements&#x201D; regarding collaboration agreement with Astellas.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px" align="justify"><font style="FONT-FAMILY: 'Times New Roman'" size="2">Drug candidates developed by the Company may require approvals or clearances from the U.S.&#xA0;Food and Drug Administration (&#x201C;FDA&#x201D;) or international regulatory agencies prior to commercialized sales. There can be no assurance that the Company&#x2019;s drug candidates will receive any of the required approvals or clearances. If the Company was to be denied approval or clearance or any such approval or clearance was to be delayed, it would have a material adverse impact on the Company.</font></p> <p style="MARGIN-BOTTOM: 0px; WHITE-SPACE: normal; TEXT-TRANSFORM: none; WORD-SPACING: 0px; COLOR: rgb(0,0,0); FONT: medium 'Times New Roman'; MARGIN-TOP: 12px; LETTER-SPACING: normal; TEXT-INDENT: 4%; -webkit-text-stroke-width: 0px" align="justify"><font style="FONT-FAMILY: 'Times New Roman'" size="2">The Company&#x2019;s operations and employees are located in the United States. In the year ended December&#xA0;31, 2013, 66% of the Company&#x2019;s revenues were received from entities located in the United States and 34% were received from a Japanese entity. In the years ended 2012 and 2011, all of the Company&#x2019;s revenues were received from entities located in the United States or from United States affiliates of foreign corporations.</font></p> </div>
CY2013 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.04 pure
CY2013 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
12.55
CY2013 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.02 pure
CY2013 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
10200000 shares
CY2013 us-gaap Use Of Estimates
UseOfEstimates
<div> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-LEFT: 2%; MARGIN-TOP: 18pt"> <b><i>Use of Estimates</i></b></p> <p style="MARGIN-BOTTOM: 0pt; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman; MARGIN-TOP: 6pt; TEXT-INDENT: 4%"> The preparation of financial statements in conformity with accounting principles generally accepted in the United States requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.</p> </div>
CY2013 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-623000
CY2013 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
11.10
CY2013 us-gaap Revenues
Revenues
30648000
CY2013 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-818000
CY2013 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-33728000
CY2013 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
79000
CY2013 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2013 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-33717000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-33717000
CY2013 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
114000
CY2013 us-gaap Investment Income Interest
InvestmentIncomeInterest
792000
CY2013 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
79434000
CY2013 us-gaap Profit Loss
ProfitLoss
-33717000
CY2013 us-gaap Revenue From Grants
RevenueFromGrants
94000
CY2013 us-gaap Operating Income Loss
OperatingIncomeLoss
-33894000
CY2013 us-gaap Interest And Other Income
InterestAndOtherIncome
98000
CY2013 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
4000000
CY2013 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13700000
CY2013 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-33717000
CY2013 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
177000
CY2013 us-gaap Net Income Loss
NetIncomeLoss
-33717000
CY2013 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
78444000
CY2013 us-gaap Depreciation
Depreciation
400000
CY2013 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3597000
CY2013 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2013 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
1656000
CY2013 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2013 cytk Issuance Of Common Stock To Related Party For Cash Per Share
IssuanceOfCommonStockToRelatedPartyForCashPerShare
7.12
CY2013 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
-2000
CY2013 cytk Non Cancelable Lease Expiration Year
NonCancelableLeaseExpirationYear
2018
CY2013 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
-11000
CY2013 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
55000
CY2013 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3597000
CY2013 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
542000
CY2013 us-gaap License And Services Revenue
LicenseAndServicesRevenue
3852000
CY2013 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
193000
CY2013 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
60000000
CY2013 us-gaap Costs And Expenses
CostsAndExpenses
64542000
CY2013 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
15092000
CY2013 us-gaap Adjustments To Additional Paid In Capital Stock Split
AdjustmentsToAdditionalPaidInCapitalStockSplit
139000
CY2013 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
14488000
CY2013 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2013 us-gaap Increase Decrease In Deferred Revenue
IncreaseDecreaseInDeferredRevenue
16201000
CY2013 us-gaap Interest And Debt Expense
InterestAndDebtExpense
-79000
CY2013 us-gaap Share Based Compensation
ShareBasedCompensation
3597000
CY2013 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
5251000
CY2013 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2013 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3306000
CY2013 us-gaap Defined Contribution Plan Employer Discretionary Contribution Amount
DefinedContributionPlanEmployerDiscretionaryContributionAmount
0
CY2013 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
3523000
CY2013 us-gaap Interest Expense
InterestExpense
CY2013 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
13000
CY2013 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2013 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-1519000
CY2013 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
49450000
CY2013 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
-150000
CY2013 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2013 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
433000
CY2013 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2013 cytk License Revenues From Related Parties
LicenseRevenuesFromRelatedParties
17230000
CY2013 cytk Related Party Research And Development Revenue
RelatedPartyResearchAndDevelopmentRevenue
2019000
CY2013 cytk Percentage Of Income Tax Positions Likely To Be Realized
PercentageOfIncomeTaxPositionsLikelyToBeRealized
0.50 pure
CY2013 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.01 pure
CY2013 cytk Issuance Of Common Stock To Related Party Issuance Costs
IssuanceOfCommonStockToRelatedPartyIssuanceCosts
21
CY2013 cytk Fractional Shares From Reverse Stock Split Share
FractionalSharesFromReverseStockSplitShare
0 shares
CY2013 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
7547000
CY2013 cytk Warrant Expense
WarrantExpense
CY2013 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
117394 shares
CY2013 cytk Proceeds From Other Issuances Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOtherIssuancesOfCommonStockAndWarrantsNetOfIssuanceCosts
7038000
CY2013 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
3.66
CY2013 cytk Proceeds From Initial And Subsequent Public Offering And Sale To Related Party Net Of Issuance Costs
ProceedsFromInitialAndSubsequentPublicOfferingAndSaleToRelatedPartyNetOfIssuanceCosts
7450000
CY2013 cytk Share Based Compensation Arrangement By Share Based Payment Shares Available For Grant Award Options Exercised In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentSharesAvailableForGrantAwardOptionsExercisedInPeriodGross
shares
CY2013 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Trade In Value
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredTradeInValue
81000
CY2013 cytk Cash Requirements Term
CashRequirementsTerm
P12M
CY2013 cytk Stock Issued During Period Value New Issues To Related Party
StockIssuedDuringPeriodValueNewIssuesToRelatedParty
7450000
CY2013 cytk Stock Issued During Period Value Exercise Of Warrants
StockIssuedDuringPeriodValueExerciseOfWarrants
5000
CY2012 us-gaap Repayments Of Secured Debt
RepaymentsOfSecuredDebt
152000
CY2012 us-gaap Revenue From Grants
RevenueFromGrants
1308000
CY2012 us-gaap Operating Income Loss
OperatingIncomeLoss
-40457000
CY2012 us-gaap Interest And Other Income
InterestAndOtherIncome
89000
CY2012 us-gaap Interest Paid
InterestPaid
3000
CY2012 us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
2139000
CY2012 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
21100000
CY2013 cytk Research And Development Federal Tax Credit Carryforwards Expiration Date Year
ResearchAndDevelopmentFederalTaxCreditCarryforwardsExpirationDateYear
2021
CY2013 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.41 pure
CY2013 cytk Proceeds From Issuance Or Sale Of Stock And Warrant
ProceedsFromIssuanceOrSaleOfStockAndWarrant
56000000
CY2013 cytk Non Cancelable Lease Additional Extension Period
NonCancelableLeaseAdditionalExtensionPeriod
P3Y
CY2013 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.07 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Number Of Additional Shares Authorized
ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
416667 shares
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Shares Issued In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
403108 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
-0.34 pure
CY2012 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0.00 pure
CY2012 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
18107000 shares
CY2012 us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
6.14
CY2012 us-gaap Effective Income Tax Rate Reconciliation Other Adjustments
EffectiveIncomeTaxRateReconciliationOtherAdjustments
0.01 pure
CY2012 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-33438000
CY2012 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-2.30
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
403108 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
-0.19 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
210989 shares
CY2012 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.06 pure
CY2012 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
17.00
CY2012 us-gaap Effective Income Tax Rate Reconciliation Nondeductible Expense Share Based Compensation Cost
EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost
0.00 pure
CY2012 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
14866000 shares
CY2012 us-gaap Revenues
Revenues
7559000
CY2012 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
320000
CY2012 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-40355000
CY2012 us-gaap Gain Loss On Sale Of Property Plant Equipment
GainLossOnSaleOfPropertyPlantEquipment
2000
CY2012 us-gaap Income Taxes Paid Net
IncomeTaxesPaidNet
1000
CY2012 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-41677000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
CY2012 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
13761000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-40370000
CY2012 us-gaap Investment Income Interest
InvestmentIncomeInterest
83000
CY2012 us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
92788000
CY2012 us-gaap Profit Loss
ProfitLoss
-40370000
CY2012 us-gaap Income Loss From Continuing Operations Before Income Taxes Minority Interest And Income Loss From Equity Method Investments
IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
-40370000
CY2012 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
87000
CY2012 us-gaap Net Income Loss
NetIncomeLoss
-40370000
CY2012 us-gaap Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures
StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures
-401000
CY2012 us-gaap Other Comprehensive Income Loss Net Of Tax
OtherComprehensiveIncomeLossNetOfTax
15000
CY2012 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
65000
CY2012 us-gaap Increase Decrease In Due From Related Parties Current
IncreaseDecreaseInDueFromRelatedPartiesCurrent
-10000
CY2012 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3783000
CY2012 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
125000
CY2012 us-gaap Increase Decrease In Restricted Cash
IncreaseDecreaseInRestrictedCash
-196000
CY2012 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
12318000
CY2012 us-gaap Noncash Or Part Noncash Acquisition Fixed Assets Acquired1
NoncashOrPartNoncashAcquisitionFixedAssetsAcquired1
116000
CY2012 us-gaap Costs And Expenses
CostsAndExpenses
48016000
CY2012 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
12429000
CY2012 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
58327000
CY2012 us-gaap Deferred Income Tax Expense Benefit
DeferredIncomeTaxExpenseBenefit
CY2012 us-gaap Interest And Debt Expense
InterestAndDebtExpense
2000
CY2012 us-gaap Share Based Compensation
ShareBasedCompensation
3783000
CY2012 us-gaap Cash And Cash Equivalents Period Increase Decrease
CashAndCashEquivalentsPeriodIncreaseDecrease
-3926000
CY2012 us-gaap Current State And Local Tax Expense Benefit
CurrentStateAndLocalTaxExpenseBenefit
CY2012 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
3375000
CY2012 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
2098000
CY2012 us-gaap Interest Expense
InterestExpense
3000
CY2012 us-gaap Proceeds From Sale Of Property Plant And Equipment
ProceedsFromSaleOfPropertyPlantAndEquipment
2000
CY2012 us-gaap Deferred Federal Income Tax Expense Benefit
DeferredFederalIncomeTaxExpenseBenefit
CY2012 us-gaap Restructuring Costs And Asset Impairment Charges
RestructuringCostsAndAssetImpairmentCharges
-56000
CY2012 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28815000
CY2012 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
35643000
CY2012 us-gaap Increase Decrease In Due To Related Parties Current
IncreaseDecreaseInDueToRelatedPartiesCurrent
138000
CY2012 us-gaap Deferred State And Local Income Tax Expense Benefit
DeferredStateAndLocalIncomeTaxExpenseBenefit
CY2012 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
591000
CY2012 us-gaap Current Income Tax Expense Benefit
CurrentIncomeTaxExpenseBenefit
CY2012 us-gaap Proceeds From Sale And Maturity Of Available For Sale Securities
ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities
63900000
CY2012 us-gaap Restructuring Charges
RestructuringCharges
-56000
CY2012 us-gaap Depreciation
Depreciation
600000
CY2012 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3783000
CY2012 us-gaap Other Preferred Stock Dividends And Adjustments
OtherPreferredStockDividendsAndAdjustments
1307000
CY2012 us-gaap Current Federal Tax Expense Benefit
CurrentFederalTaxExpenseBenefit
CY2012 us-gaap Increase Decrease In Accounts Payable Trade
IncreaseDecreaseInAccountsPayableTrade
690000
CY2012 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
CY2012 cytk Noncash Or Part Noncash Acquisition Fixed Assets Acquired Through Accrued Liabilities
NoncashOrPartNoncashAcquisitionFixedAssetsAcquiredThroughAccruedLiabilities
37000
CY2012 cytk Adjustments To Additional Paid In Capital Issuance Of Convertible Preferred Stock
AdjustmentsToAdditionalPaidInCapitalIssuanceOfConvertiblePreferredStock
12318000
CY2012 cytk Proceeds From Draw Down Of Committed Equity Financing Facilities And At Market Facility Net Of Issuance Costs
ProceedsFromDrawDownOfCommittedEquityFinancingFacilitiesAndAtMarketFacilityNetOfIssuanceCosts
2820000
CY2012 cytk Related Party Research And Development Revenue
RelatedPartyResearchAndDevelopmentRevenue
4177000
CY2012 cytk Stock Issued During Period Value Securities Purchase Agreement
StockIssuedDuringPeriodValueSecuritiesPurchaseAgreement
29916000
CY2012 cytk Effective Income Tax Rate Reconciliation Net Operating Loss Expiration
EffectiveIncomeTaxRateReconciliationNetOperatingLossExpiration
0.02 pure
CY2012 cytk Research And Development Grant And Other Revenues
ResearchAndDevelopmentGrantAndOtherRevenues
3382000
CY2012 cytk Warrant Expense
WarrantExpense
CY2012 cytk Shares Available For Grant Of Options Or Awards Options Forfeited Expired
SharesAvailableForGrantOfOptionsOrAwardsOptionsForfeitedExpired
210989 shares
CY2012 cytk Proceeds From Other Issuances Of Common Stock And Warrants Net Of Issuance Costs
ProceedsFromOtherIssuancesOfCommonStockAndWarrantsNetOfIssuanceCosts
-336000
CY2012 cytk Issuance Of Common Stock Employee Stock Purchase Plan Price Per Share
IssuanceOfCommonStockEmployeeStockPurchasePlanPricePerShare
4.32
CY2012 cytk Proceeds From Initial And Subsequent Public Offering And Sale To Related Party Net Of Issuance Costs
ProceedsFromInitialAndSubsequentPublicOfferingAndSaleToRelatedPartyNetOfIssuanceCosts
43677000
CY2012 cytk Effective Income Tax Rate Reconciliation Deferred Tax Assets Utilized Not Benefited
EffectiveIncomeTaxRateReconciliationDeferredTaxAssetsUtilizedNotBenefited
0.56 pure
CY2012 cytk Issuance Cost Of Warrant
IssuanceCostOfWarrant
984000
CY2012 cytk Effective Income Tax Rate Reconciliation State Apportionment
EffectiveIncomeTaxRateReconciliationStateApportionment
0.00 pure
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.53
CY2013Q1 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.53
CY2013Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12619000
CY2013Q1 us-gaap Net Income Loss
NetIncomeLoss
-12619000
CY2013Q1 us-gaap Sales Revenue Net
SalesRevenueNet
821000
CY2012Q1 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.78
CY2012Q1 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9928000
CY2012Q1 us-gaap Net Income Loss
NetIncomeLoss
-9928000
CY2012Q1 us-gaap Sales Revenue Net
SalesRevenueNet
1820000
CY2012Q2 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.76
CY2012Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10250000
CY2012Q2 us-gaap Net Income Loss
NetIncomeLoss
-8943000
CY2012Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1841000
CY2012Q2 us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
32100000
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.58
CY2013Q2 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.58
CY2013Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-15041000
CY2013Q2 us-gaap Net Income Loss
NetIncomeLoss
-15041000
CY2013Q2 us-gaap Sales Revenue Net
SalesRevenueNet
1009000
CY2012Q3 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.45
CY2012Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-10044000
CY2012Q3 us-gaap Net Income Loss
NetIncomeLoss
-10044000
CY2012Q3 us-gaap Sales Revenue Net
SalesRevenueNet
1714000
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
-0.43
CY2013Q3 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
-0.43
CY2013Q3 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-12588000
CY2013Q3 us-gaap Net Income Loss
NetIncomeLoss
-12588000
CY2013Q3 us-gaap Sales Revenue Net
SalesRevenueNet
4469000
CY2011Q4 cytk Restructuring Charges Personnel Related Termination Costs
RestructuringChargesPersonnelRelatedTerminationCosts
1200000
CY2012Q4 us-gaap Income Loss From Continuing Operations Per Basic And Diluted Share
IncomeLossFromContinuingOperationsPerBasicAndDilutedShare
-0.48
CY2012Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-11455000
CY2012Q4 us-gaap Net Income Loss
NetIncomeLoss
-11455000
CY2012Q4 us-gaap Sales Revenue Net
SalesRevenueNet
2184000
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Basic Share
IncomeLossFromContinuingOperationsPerBasicShare
0.22
CY2013Q4 us-gaap Income Loss From Continuing Operations Per Diluted Share
IncomeLossFromContinuingOperationsPerDilutedShare
0.21
CY2013Q4 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
6531000
CY2013Q4 us-gaap Net Income Loss
NetIncomeLoss
6531000
CY2013Q4 us-gaap Sales Revenue Net
SalesRevenueNet
24349000

Files In Submission

Name View Source Status
0001193125-14-089045-index-headers.html Edgar Link pending
0001193125-14-089045-index.html Edgar Link pending
0001193125-14-089045.txt Edgar Link pending
0001193125-14-089045-xbrl.zip Edgar Link pending
cytk-20131231.xml Edgar Link completed
cytk-20131231.xsd Edgar Link pending
cytk-20131231_cal.xml Edgar Link unprocessable
cytk-20131231_def.xml Edgar Link unprocessable
cytk-20131231_lab.xml Edgar Link unprocessable
cytk-20131231_pre.xml Edgar Link unprocessable
d630471d10k.htm Edgar Link pending
d630471dex1039.htm Edgar Link pending
d630471dex231.htm Edgar Link pending
d630471dex311.htm Edgar Link pending
d630471dex312.htm Edgar Link pending
d630471dex321.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xls Edgar Link pending
Financial_Report.xlsx Edgar Link pending
g630471g43u54.jpg Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R65.htm Edgar Link pending
R66.htm Edgar Link pending
R67.htm Edgar Link pending
R68.htm Edgar Link pending
R69.htm Edgar Link pending
R7.htm Edgar Link pending
R70.htm Edgar Link pending
R71.htm Edgar Link pending
R72.htm Edgar Link pending
R73.htm Edgar Link pending
R74.htm Edgar Link pending
R75.htm Edgar Link pending
R76.htm Edgar Link pending
R77.htm Edgar Link pending
R78.htm Edgar Link pending
R79.htm Edgar Link pending
R8.htm Edgar Link pending
R80.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending